BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Puchner R, Edlinger M, Mur E, Eberl G, Herold M, Kufner P, Puchner A, Puchner SE, Redlich K, Alkin A, Machold K. Interface Management between General Practitioners and Rheumatologists-Results of a Survey Defining a Concept for Future Joint Recommendations. PLoS One 2016;11:e0146149. [PMID: 26741702 DOI: 10.1371/journal.pone.0146149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, Balato A. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front Immunol 2018;9:1668. [PMID: 30150978 DOI: 10.3389/fimmu.2018.01668] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 13.3] [Reference Citation Analysis]
3 Viguier M, Rist S, Aubin F, Leccia MT, Richard MA, Esposito-Farèse M, Gaudin P, Pham T, Richette P, Wendling D, Sibilia J, Tubach F; Club Rhumatismes et Inflammation. Online training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based survey. PLoS One 2015;10:e0127564. [PMID: 25996152 DOI: 10.1371/journal.pone.0127564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
5 Terlemez R, Akgün K, Palamar D, Boz S, Sarı H. The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Clin Rheumatol 2017;36:1071-6. [PMID: 28357602 DOI: 10.1007/s10067-017-3607-8] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Kim BS, Maverakis E, Alexanian C, Wang JZ, Raychaudhuri SP. Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review. J Cutan Med Surg 2020;24:278-84. [PMID: 32238066 DOI: 10.1177/1203475420914622] [Reference Citation Analysis]
7 Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Dig Dis Sci. 2016;61:2132-2139. [PMID: 26846115 DOI: 10.1007/s10620-016-4042-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
8 Krüger K, Albrecht K, Rehart S, Scholz R; Kommission Pharmakotherapie der DGRh. [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. Z Rheumatol 2014;73:77-84. [PMID: 24310229 DOI: 10.1007/s00393-013-1301-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
9 Banse C, Bisson-Vaivre A, Kozyreff-Meurice M, Vittecoq O, Goëb V. No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. Int J Gen Med 2013;6:605-11. [PMID: 23901289 DOI: 10.2147/IJGM.S44542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
10 Celada LJ, Drake WP. Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy? Immunotherapy 2015;7:57-66. [PMID: 25572480 DOI: 10.2217/imt.14.103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int 2014;34:151-63. [PMID: 24322451 DOI: 10.1007/s00296-013-2907-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]